🔎 Trials Near Me

Hjem › Blærecancer › Texas

Blærecancer kliniske forsøg i Texas

51 studier for Blærecancer søger deltagere på steder i Texas.

Byer i Texas

Officiel studietekst (engelsk)

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University of Texas MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics (START), San Antonio
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06465069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • The Don and Sybil Harrington Cancer Center, Amarillo
  • UT MD Anderson Cancer Center, Houston
  • Audie L Murphy VA Hospital, San Antonio
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06760819

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

  • Texas Oncology-Austin Central ( Site 0107), Austin
  • Urology Austin, PLLC ( Site 0109), Austin
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06833073

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06172478

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center - Conroe, Conroe
  • University of Texas MD Anderson Cancer Center, Houston
  • The University of Texas, MD Anderson Cancer Center - West Houston, Houston
  • og 3 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07090499

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  • Parkland Memorial Hospital, Dallas
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • og 5 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07061964

Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer

  • UT Southwestern Medical Center, Dallas
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06394570

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

  • Texas Oncology, Austin
  • Texas Oncology - Northeast Texas, Tyler
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07566156

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • og 1 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT03866382

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  • Texas Oncology - Central/South Texas, Austin
  • Texas Oncology - Central/South Texas, Austin
  • Texas Oncology - Central/South Texas, Austin
  • og 13 flere
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07421700

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

  • Cancer Center Outpatient Building, Dallas
  • The University of Texas Southwestern Medical Center, Dallas
  • UT Southwestern Medical Center - West Campus Building, Dallas
  • og 5 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07206225

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • START Dallas Fort Worth, Fort Worth
  • MD Anderson, Houston
  • NEXT Oncology Houston, Houston
  • og 1 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07277413

DESTINY-PANTUMOUR04

  • Research Site, Dallas
RekruttererObservationsstudie
Alder 18 til 130 · Alle køn · Opdateret 25. sep. 2026 · NCT07124000

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  • USO-Texas Oncology-Central/South Texas, Austin
  • World Research Link, Baytown
  • Parkland Health and Hospital System, Dallas
  • og 5 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07218380

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

  • Texas Oncology (Balcones) - SCRI, Austin
  • MD Anderson Cancer Center, Houston
  • START South Texas Accelerated Research Therapeutics, San Antonio
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT05267626

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

  • MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT07217171

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • UT Southwestern Medical Center, Dallas
  • DHR Health Advance Care Center, Edinburg
  • The Center for Cancer and Blood Disorders, Forth Worth
  • og 1 flere
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT05059444

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

  • Urology Austin, PLLC ( Site 0008), Austin
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT07222488

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

  • UPNT Research Institute, LLC, Arlington
  • Urology Austin, PLLC (Urology America), Austin
  • Urology Clinics of North Texas, PLLC, Dallas
  • og 3 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT06567743

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

  • Urology Partners of North Texas, Arlington
  • Urology Austin, LLC, Austin
  • Houston Metro Urology, Houston
  • og 2 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. aug. 2026 · NCT05951179

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

  • University of Texas Southwestern Medical Center, Dallas
  • University of Texas Health Science Center at San Antonio, San Antonio
RekruttererObservationsstudie
Alder 18 til 99 · Alle køn · Opdateret 24. aug. 2026 · NCT05825950

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

  • Urology Partners of North Texas, Arlington
  • Houston Metro Urology, Houston
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 21. aug. 2026 · NCT07480356

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

  • University of Texas Southwestern, Dallas
  • Texas Oncology, P.A, Dallas
  • MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT05614739

Measuring Surgical Recovery After Radical Cystectomy

  • University of Texas - Southwestern, Dallas
  • University of Texas MD Anderson Cancer Center, Houston
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT03193970

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  • MD Anderson in The Woodlands, Conroe
  • Parkland Memorial Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • og 4 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT07097142

A Study of MGC026 in Participants With Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • University of Texas Health Science Center at Houston, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 11. aug. 2026 · NCT06242470

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • The University of Texas, MD Anderson Cancer Center, Houston
  • UT Health Mays Cancer Center, San Antonio
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. aug. 2026 · NCT05592626

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

  • Urology Austin, Austin
  • UT Southwestern Medical Center, Dallas
  • Houston Metro Urology, Houston
  • og 2 flere
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 7. aug. 2026 · NCT04752722

IDOV-Immune for Advanced Solid Tumors

  • MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics, San Antonio
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT06910657

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  • Texas Oncology - West Texas, Abilene
  • Local Institution - 0187, Austin
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 29. jul. 2026 · NCT07106762

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • Baylor Scott & White Research Institute, Dallas
  • University of Texas MD Anderson Cancer Center, Houston
  • Baylor Scott & White Medical Center, Temple
RekruttererFase 2
Alder 8 og opefter · Alle køn · Opdateret 27. jul. 2026 · NCT05503797

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  • Research Site, Dallas
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT07720284

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  • Baylor Scott and White Research Institute, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
  • Baylor Scott & White Medical Center - Temple, Temple
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT04879329

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

  • NEXT Dallas, Dallas
  • MD Anderson Cancer Center, Houston
  • NEXT Houston, Houston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 7. jul. 2026 · NCT07337525

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Oncology Consultants, PA, Houston
  • Oncology Consultants, PA., Houston
  • The University of Texas M.D. Anderson Cancer Center, Houston
  • og 5 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. jul. 2026 · NCT04389632

Predicting BCG Response

  • University of Texas Southwestern, Dallas
RekruttererObservationsstudie
Alder 18 til 90 · Alle køn · Opdateret 6. jul. 2026 · NCT04564781

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

  • Austin Urology Institute, Austin
  • UT Southwestern Medical Center, Dallas
Rekrutterer
Alder 18 til 88 · Alle køn · Opdateret 2. jul. 2026 · NCT06394869

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

  • JPS Health Network, Forth Worth
  • Baylor Scott and White Biorepository, Temple
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 29. jun. 2026 · NCT07327489

Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.